Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Medifast (MED) Capital Expenditures (2016 - 2025)

Medifast's Capital Expenditures history spans 16 years, with the latest figure at $1.4 million for Q4 2025.

For Q4 2025, Capital Expenditures fell 40.88% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.6 million, down 24.68%, while the annual FY2025 figure was $5.6 million, 24.68% down from the prior year.
Capital Expenditures reached $1.4 million in Q4 2025 per MED's latest filing, down from $1.4 million in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $11.6 million in Q4 2021 to a low of $946000.0 in Q4 2023.
Average Capital Expenditures over 5 years is $3.5 million, with a median of $1.9 million recorded in 2024.
Peak YoY movement for Capital Expenditures: surged 2529.07% in 2021, then plummeted 89.56% in 2023.
A 5-year view of Capital Expenditures shows it stood at $11.6 million in 2021, then fell by 22.02% to $9.1 million in 2022, then tumbled by 89.56% to $946000.0 in 2023, then skyrocketed by 141.54% to $2.3 million in 2024, then plummeted by 40.88% to $1.4 million in 2025.
Per Business Quant, the three most recent readings for MED's Capital Expenditures are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).